Azelaic acid 140 MG/ML Topical Cream — RxCUI 2738813
RxNorm drug concept · Semantic clinical drug
RxCUI 2738813
Semantic clinical drug · SCD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2738813
Official nameAzelaic acid 140 MG/ML Topical Cream
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asazelaic acid 14 % Topical Cream
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Azelaic Acid Topical: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It's used to treat the red bumps and pimples that come with mild to moderate rosacea — a chronic skin condition that mainly affects the face. It's applied directly to the skin, not...
- Yes, that's actually one of the most commonly reported side effects, especially in the first few weeks of use. It usually settles down as your skin adjusts. That said, if the irrit...
- My skin is burning and stinging after I apply it — is that normal?
- Shake the can well before each use. Gently wash your face with a mild cleanser, pat it dry, then apply a thin layer of foam to your whole face — cheeks, chin, forehead, and nose —...
🕸️ Concept Web — How Azelaic acid 140 MG/ML Topical Cream Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Azelaic acid 140 MG/ML Topical Cream
RxCUI 2738813 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Azelate
618278IN -
Azelaic acid
18602PIN
-
Azelate
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Azelate Topical Cream
618280SCDF -
Azelaic acid Topical Cream
2648774SCDFP -
Azelate Topical Product
1155005SCDG -
Azelaic acid Topical Product
2662121SCDGP -
Topical Cream
316982DF -
Topical Product
1151122DFG
-
Azelate Topical Cream
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Azelaic acid 140 MG/ML
2738812SCDC
-
Azelaic acid 140 MG/ML
Showing up to 8 concepts per family — 9 of 9 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Azelaic acid 140 MG/ML
SCDC · 2738812 -
Azelate Topical Cream
SCDF · 618280 -
Azelaic acid Topical Cream
SCDFP · 2648774 -
Azelate Topical Product
SCDG · 1155005 -
Azelaic acid Topical Product
SCDGP · 2662121
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 2738813 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 84753-0056-01 | 30 g in 1 BOTTLE (84753-056-01) | 14% Azelaic Acid Acne | Guangdong Bisutang Biotechnology Co., Ltd. | 2026-03-12 |
| 87386-0002-01 | 1 BOTTLE, DROPPER in 1 BOX (87386-002-01) / 40 g in 1 BOTTL... | Bloomellee 14%Gel Azelaic Acid Cream | Shenzhen Lanxi Trading Co., Ltd. | 2026-05-25 |
Observed labelers:
Guangdong Bisutang Biotechnology Co., Ltd. (1) ·
Shenzhen Lanxi Trading Co., Ltd. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.